Federal contract award
75A50124C00062
DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | Q701 — Specialized Medical Support |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $14.2M |
| Current contract value | $14.2M |
| Potential contract value / ceiling | $231.1M |
| Start date | Sep 30, 2024 |
| Current end date | Dec 31, 2026 |
| Potential end date | Sep 30, 2029 |
| Latest award activity | Apr 27, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 27, 2026 | P00004 | $4.8M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE ADDITIONAL FUNDING FOR CLIN 0001 IN THE AMOUNT OF $4,839,729.00. 2. EXTEND CLIN 0001 PERIOD OF PERFORMANCE TO 31 DEC 2026. 3. UPDATE SOW TO REVISION V20MAR2026. |
| Feb 25, 2026 | P00003 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. EXTEND THE BASE PERIOD, CLIN 0001, AT NO ADDITIONAL COST THROUGH 31 MAY 2026. 2. INCLUDE PROVISIONAL INDIRECT AND FRINGE RATES. |
| Dec 29, 2025 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. EXTEND THE BASE PERIOD, CLIN 0001, AT NO ADDITIONAL COST THROUGH 28 FEBRUARY 2026. |
| Nov 5, 2025 | P00001 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. UPDATE SOW 2. ADD ALTERNATE COR |
| Sep 27, 2024 | 0 | $9.4M | DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC |
Estimated positioning window
Sep 30, 2028 – Mar 30, 2029
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-09-30 (1064 days from calculation)
- +15 points
- 4 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2026-04-27
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.